Interestingly, Chen and colleagues reported a strong tendency for PTEN, PHLPP1, PHLPP2, and TP53 co-deletion in metastatic prostate cancer and that low PHLPP1 expression correlates with reduced patient survival and relapse after surgery [138]. This evidence concerns the gene PTEN and metastatic prostate carcinoma.